Tranexamic Acid vs. Hydroquinone vs. Kojic Acid: The Brightening Hierarchy
Compare tranexamic acid, hydroquinone, and kojic acid for melasma: mechanism, clinical evidence, safety, and a sensible escalation guide.
For melasma, the evidence points to a clear escalation ladder: kojic acid (gentlest, good for mild cases), tranexamic acid (strong evidence, well-tolerated long-term), and hydroquinone (the most studied benchmark, but regulated and used in time-limited courses under a dermatologist). Your starting point depends on your skin tone, region, and how long the pigmentation has been there.
What Causes Melasma in the First Place?
Melasma is a pigmentary condition driven by overactive melanocytes, the cells that produce melanin. UV exposure, hormonal shifts, and heat all push those cells to overproduce pigment, resulting in the patchy brown or grey discolouration most often seen across the cheeks, forehead, and upper lip.
All three actives discussed here target melanin production, but they do it through different mechanisms and at different points in the pathway. Understanding that distinction is what helps you pick the right tool and set realistic expectations about timelines.
How Does Hydroquinone Work, and What Are the Risks?
Hydroquinone remains the most studied depigmenting agent worldwide. It works primarily by inhibiting tyrosinase, the rate-limiting enzyme in melanin synthesis, while also interfering with DNA and RNA synthesis in melanocytes. At 4%, it is effective: a large systematic review covering 113 randomised controlled trials confirmed hydroquinone monotherapy as one of the best-studied topical treatments for melasma 1.
The limitations are significant. Hydroquinone is prescription-only in the United States (products at 2% and above require a prescription as of 2020) and is banned from cosmetics in the European Union, Japan, and Australia. Long-term or high-concentration use can cause exogenous ochronosis, an irreversible blue-black discolouration, and it is not appropriate for indefinite use. Courses are typically capped at 5 to 6 months under dermatologist supervision.
If you are considering hydroquinone, that conversation must happen with a qualified dermatologist who can confirm it is appropriate for your skin and monitor for adverse effects.
How Does Tranexamic Acid Work?
Tranexamic acid is an antifibrinolytic drug with an unexpected skin application. It blocks the binding of plasminogen to keratinocytes, which reduces UV-triggered prostaglandin release, which in turn reduces melanocyte-stimulating hormone activity. Less melanocyte stimulation means less pigment.
The clinical data is encouraging. In a rigorous split-face study of 100 patients, 5% tranexamic acid cream produced equivalent MASI score improvement to 4% hydroquinone after 12 weeks, with significantly fewer side effects reported in the tranexamic acid group 2. The network meta-analysis by Liu et al. (59 RCTs) ranked oral tranexamic acid above hydroquinone on the efficacy ladder for melasma 3.
Topical tranexamic acid is available at concentrations of 3% to 5% in over-the-counter formulations in most regions. Oral tranexamic acid is prescription-only and requires screening for clot-risk factors before use. Persistent melasma that does not respond to topical treatment warrants assessment by a dermatologist.
How Does Kojic Acid Work?
Kojic acid is a naturally occurring compound derived from fungal fermentation. It inhibits tyrosinase by chelating copper ions at the enzyme's active site, disrupting the conversion of tyrosine to melanin. In head-to-head biochemical comparisons, kojic acid's tyrosinase inhibition is weaker than hydroquinone at equivalent concentrations, though the two are often combined precisely because they act at different points in the pathway 3.
In practice, it works well for mild to moderate hyperpigmentation. A randomised trial in 80 melasma patients found that 1% kojic acid alone reduced MASI scores over 12 weeks, while the combination of 1% kojic acid plus 2% hydroquinone produced the highest improvement of the four groups tested 4.
Kojic acid is typically used at 1% to 2% in OTC products. It is well-tolerated by most skin types, though some people experience contact dermatitis, particularly at higher concentrations or with repeated use. It is widely available without a prescription.
Comparing the Three: Mechanism, Evidence, and Safety
| Kojic Acid | Tranexamic Acid | Hydroquinone | |
|---|---|---|---|
| Typical OTC concentration | 1-2% | 3-5% (topical) | Prescription-only in US, banned in EU |
| Primary mechanism | Tyrosinase copper chelation | Reduces melanocyte stimulation via plasminogen pathway | Tyrosinase inhibition + melanocyte toxicity |
| Clinical evidence strength | Moderate | Strong (topical and oral RCTs) | Very strong (most studied) |
| Long-term use | Generally fine | Yes, topical; oral requires monitoring | Time-limited courses (5-6 months) |
| Key risk | Contact dermatitis in some | Oral: clot risk screening needed | Ochronosis, regulatory restrictions |
| Prescription needed | No | Topical: no. Oral: yes | Yes (US); Banned OTC (EU, AU, JP) |
| Good for | Mild spots, sensitive skin | Melasma, ongoing maintenance | Moderate to severe, supervised |
What Does the Evidence Hierarchy Look Like?
Based on a network meta-analysis of 59 randomised controlled trials, the ranking of efficacy against placebo for topical melasma treatments puts oral tranexamic acid above hydroquinone and topical tranexamic acid, with hydroquinone falling lower in the ranked list partly due to its side effect burden factoring into clinical recommendations 3.
That said, hydroquinone's very long evidence trail means it is not going anywhere as a clinical tool. Triple combination cream (hydroquinone 4% plus tretinoin plus a corticosteroid) remains the most effective topical regimen for melasma overall 1. The shift in practice is not that hydroquinone is wrong, but that tranexamic acid offers a sustained-use option without the same regulatory and safety ceiling.
Side effect rates from the same meta-analysis: oral tranexamic acid 17.6%, hydroquinone 18.2%, topical tranexamic acid 36.75% (partly because many topical TA trials used high-concentration or combined formulations) 3.
How Long Before You See Results?
For all three actives, realistic timelines are:
- Kojic acid 1-2%: 8 to 12 weeks for visible reduction in mild spots.
- Topical tranexamic acid 3-5%: 8 to 12 weeks; significant improvement in MASI scores was documented at 12 weeks in comparative trials 2.
- Hydroquinone 4% (under supervision): 4 to 8 weeks for initial fading; treatment courses typically run 3 to 6 months then pause.
All three require daily SPF use. UV exposure will override any brightening active. No treatment for melasma works without photoprotection.
FAQ
Is tranexamic acid safer than hydroquinone for long-term use?
For topical formulations, yes. Topical tranexamic acid does not carry the ochronosis risk associated with extended hydroquinone use and is not subject to the same regulatory restrictions in most regions. Oral tranexamic acid is a different question: it is prescription-only and requires a healthcare provider to screen for clot-risk factors before prescribing. Long-term oral use needs medical supervision.
Can kojic acid replace hydroquinone?
For mild to moderate hyperpigmentation, kojic acid is a reasonable first-line option, particularly where hydroquinone is unavailable or restricted. The evidence shows it works, though it is less potent than hydroquinone at comparable concentrations. It is often combined with other actives, such as niacinamide or vitamin C, to improve results.
Do these actives work on all skin tones?
Yes, but with caveats. People with deeper skin tones are at higher risk of post-inflammatory hyperpigmentation from irritant reactions, so lower concentrations and slower titration matter more. Hydroquinone has historically been used across skin tones, though the ochronosis risk is disproportionately reported in darker-skinned populations with prolonged use. Tranexamic acid has a good tolerability profile across Fitzpatrick types.
Should I use more than one of these at the same time?
Combining actives is common in clinical practice. Kojic acid plus niacinamide, or tranexamic acid plus a retinoid, are well-studied pairings. Layering two strong depigmenting agents without guidance can increase irritation risk without proportionally increasing benefit. If you are unsure what to combine, checking ingredient compatibility before building your routine is a practical first step.
When does melasma need a dermatologist?
Persistent melasma that does not respond to 12 weeks of over-the-counter treatment, melasma that keeps coming back after fading, or any situation where you are considering prescription hydroquinone or oral tranexamic acid, all warrant an in-person assessment. Melasma can look like other pigmentary conditions that need different management.
Use This in Your Routine
Before stacking a tranexamic acid serum on top of a kojic acid product, or adding either to a routine that already has retinoids and AHAs, it is worth checking how those combinations behave together. The Skin Bliss Ingredient Compatibility Checker lets you scan the specific actives in each product you are using for melasma or brightening, flag any irritation risks or duplications, and see which order makes sense for your skin. Try it at skinbliss.app.
Sources
- McKesey J, Tovar-Garza A, Pandya AG. "Melasma Treatment: An Evidence-Based Review."
- El-Husseiny R, Rakha N, Sallam M. "Efficacy and safety of tranexamic acid 5% cream vs hydroquinone 4% cream in treating melasma: A split-face comparative clinical, histopathological, and antera 3D camera study."
- Liu Y, Wu S, Wu H, et al. "Comparison of the Efficacy of Melasma Treatments: A Network Meta-Analysis of Randomized Controlled Trials."
- Deo KS, Dash KN, Sharma YK, Virmani NC, Oberai C. "Kojic Acid vis-a-vis its Combinations with Hydroquinone and Betamethasone Valerate in Melasma: A Randomized, Single Blind, Comparative Study of Efficacy and Safety."
